Neonatal sepsis
Drug research and approvals for neonatal sepsis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 28 studies of neonatal sepsis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 28
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- MDW as a Novel Diagnostic Biomarker in LONS Among Preterm NeonatesNCT07821190 · Not reported · Tanta University · starts Jul 1, 2026
- Point of Care - Sepsis StudyNCT07774013 · Not reported · Medical University of Graz · starts Aug 13, 2026
- Wireless MicroPremVitals Button Sensor in the NICUNCT07732257 · Not applicable · McGill University Health Centre/Research Institute of the McGill University Health Centre · starts Jun 19, 2026
- T6A Biomarker for Detection of Bacterial Infection in Newborn InfantsNCT07670624 · Not reported · Salzburger Landeskliniken · starts Sep 3, 2026
- Optimizing PreTerm Infant Ampicillin DosingNCT07610486 · Phase 1 / Phase 2 · Duke University · starts Jul 28, 2026
- Extended Interval Dosing of Gentamicin in NeonatesNCT07460349 · Not reported · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · starts Jun 17, 2026
- Chlorhexidine Gluconate and Alcohol Hand Rubbing on Healthcare-associated InfectionNCT07421323 · Not applicable · Alexandria University · starts Aug 1, 2025
- Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights…NCT07356583 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Feb 1, 2026
- A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaNCT07312227 · Not reported · Massachusetts General Hospital · starts Feb 11, 2026
Phase 3 8
- PentoxifyllineAdenosine A2 receptor antagonist
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- ErgocalciferolVitamin D receptor agonist
- MeropenemBacterial penicillin-binding protein inhibitor
- AzithromycinBacterial 70S ribosome inhibitor
- Ceftobiprole medocaril free acidPenicillin-binding protein 1 inhibitor
- Maltodextrin
- Lactoferrin, bovine
Phase 2 4
- VancomycinPeptidoglycan inhibitor
- ChlorhexidineCell membrane inhibitor
- FosfomycinUDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor
- Olive oil
Phase 1 or earlier 2
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- MelatoninMelatonin receptor agonist
How its trials ended
164 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 21 whose ending is known, 48% met their primary endpoint, 19% missed it and 33% stopped early.
- Completed, result not reported7244%
- Ongoing4024%
- Status unknown3119%
- Met its primary endpoint106%
- Stopped: other or unclear53%
- Missed its primary endpoint42%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA